‘World’s First’ Antibiotic Incentive Scheme Kicks Off In UK
Project Will Involve Special HTA Assessments By NICE
Executive Summary
Pharmaceutical companies are being invited to join a pioneering UK “subscription-style” scheme intended to incentivize the development of innovative antibiotics for the most serious diseases.
You may also be interested in...
Pioneering UK Payment Model For Incentivizing Antibiotic Development Meets Major Milestone
Shionogi and Pfizer are now in commercial discussions after their antibiotics were recommended for use via the UK’s new subscription-style payment model, which will ensure a fixed annual fee is paid to companies regardless of how many prescriptions are issued. The UK is urging other countries to offer similar incentives to help beat global antimicrobial resistance.
US PASTEUR Act Promises More Than Other National AMR Initiatives
PASTEUR Act in the US is the most promising initiative out there to address antimicrobial resistance.
‘A Game Changer:’ Cures 2.0 Would Provide $11bn In ‘Subscription’ Contracts For New Antibiotics
The PASTEUR Act would delink some of an antibiotic’s revenue from prescription sales, with the goal of revitalizing the antibiotic pipeline with additional private investment while encouraging good public health stewardship of critically needed medicines.